PROCEPT BioRobotics Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
PROCEPT BioRobotics Corporation (PRCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.20 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-05
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $800.00K, a 89.74% decline year-over-year.
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $1.40M, a 83.91% decline year-over-year.
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $7.60M, a 83.07% decline year-over-year.
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $7.60M, a 39.20% decline year-over-year.
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $31.70M, a 65.58% decline from fiscal 2024.
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $92.10M, a 498.05% increase from fiscal 2023.
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $15.40M, a 48.32% decline from fiscal 2022.
- PROCEPT BioRobotics Corporation share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $29.80M, a 173.39% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $800.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.20M 10-Q · filed 2026-08-05 | $9.80M derived: sum of 3 quarters · filed 2026-08-05 | $17.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.40M 10-Q · filed 2026-04-30 | $9.00M derived: sum of 2 quarters · filed 2026-04-30 | $16.60M derived: sum of 3 quarters · filed 2026-04-30 | $24.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.20M derived: sum of 2 quarters · filed 2026-02-26 | $23.00M derived: sum of 3 quarters · filed 2026-08-05 | $31.70M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $15.40M derived: sum of 2 quarters · filed 2026-08-05 | $24.10M 10-Q · filed 2025-11-05 | $69.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $16.50M 10-Q · filed 2026-08-05 | $61.40M derived: sum of 3 quarters · filed 2026-08-05 | $73.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $8.70M 10-Q · filed 2026-04-30 | $53.60M derived: sum of 2 quarters · filed 2026-04-30 | $66.10M derived: sum of 3 quarters · filed 2026-04-30 | $86.30M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $44.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $57.40M derived: sum of 2 quarters · filed 2026-02-26 | $77.60M derived: sum of 3 quarters · filed 2026-02-26 | $92.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $32.70M derived: sum of 2 quarters · filed 2025-11-05 | $47.20M 10-Q · filed 2025-11-05 | $53.70M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $20.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $34.70M 10-Q · filed 2025-08-07 | $41.20M derived: sum of 3 quarters · filed 2025-08-07 | $43.70M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $14.50M 10-Q · filed 2025-05-02 | $21.00M derived: sum of 2 quarters · filed 2025-05-02 | $23.50M derived: sum of 3 quarters · filed 2025-05-02 | $27.60M derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | $6.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $9.00M derived: sum of 2 quarters · filed 2025-02-27 | $13.10M derived: sum of 3 quarters · filed 2025-02-27 | $15.40M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-28 | $6.60M derived: sum of 2 quarters · filed 2024-10-28 | $8.90M 10-Q · filed 2024-10-28 | $10.80M derived: sum of 4 quarters · filed 2024-10-28 |
| 2023-06-30 | $4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $6.40M 10-Q · filed 2024-08-02 | $8.30M derived: sum of 3 quarters · filed 2024-08-02 | $14.50M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $2.30M 10-Q · filed 2024-05-02 | $4.20M derived: sum of 2 quarters · filed 2024-05-02 | $10.40M derived: sum of 3 quarters · filed 2024-05-02 | $23.40M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | $1.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $8.10M derived: sum of 2 quarters · filed 2024-02-28 | $21.10M derived: sum of 3 quarters · filed 2024-02-28 | $29.80M 10-K · filed 2024-02-28 |
| 2022-09-30 | $6.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $19.20M derived: sum of 2 quarters · filed 2023-11-02 | $27.90M 10-Q · filed 2023-11-02 | $33.70M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-28 | $21.70M 10-Q · filed 2023-07-28 | $27.50M derived: sum of 3 quarters · filed 2023-07-28 | |
| 2022-03-31 | $8.70M 10-Q · filed 2023-05-04 | $14.50M derived: sum of 2 quarters · filed 2023-05-04 | ||
| 2021-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $10.90M 10-K · filed 2023-02-28 | ||
| 2021-09-30 | $5.10M 10-Q · filed 2021-11-05 | |||
| 2021-03-31 | $1.50M 10-Q · filed 2022-05-06 | $1.70M derived: sum of 2 quarters · filed 2022-05-06 | ||
| 2020-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $2.00M 10-K · filed 2022-03-22 | ||
| 2020-09-30 | $1.80M 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| SpyGlass Pharma, Inc. (SGP) | United States | $0.925B | |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| SI-BONE, Inc. (SIBN) | United States | $0.830B | -49.82 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| MIMEDX GROUP, INC. (MDXG) | United States | $0.687B | 89.92 |
| ANGIODYNAMICS INC (ANGO) | United States | $0.632B | -13.02 |
| ORTHOPEDIATRICS CORP (KIDS) | United States | $0.592B |